Aptevo director converts RSUs into 400 common shares
Aptevo Therapeutics Inc. director Daniel Abdun-Nabi reported an exercise of equity awards.
Accepted by SEC EDGAR
Learn about SEC filing dates
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Aptevo Therapeutics Inc. director Daniel Abdun-Nabi reported an exercise of equity awards. On August 6, 2026, 400 Restricted Stock Units converted into 400 shares of Common Stock on a one-for-one basis. The RSU position was reduced by 400 units to zero, and direct ownership of common stock increased to 400 shares following the transaction.
Insider Trade Summary
400 shares exercised/converted
Exercise
2 txns
Insider
Abdun-Nabi Daniel
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Restricted Stock Unit F1, F2 | 400 | $0.00 | $0.00 |
| Exercise | Common Stock F1 | 400 | -- | -- |
Holdings After Transaction:
Restricted Stock Unit — 0 units (Direct);
Common Stock — 400 shares (Direct)
Footnotes (2)
- F1. Restricted Stock Units ("RSUs") convert into common stock, $0.001 par value per share, of the Issuer on a one-for-one basis.
- F2. On August 6, 2025, the reporting person was granted 7,200 (400 post-split) RSUs, vesting on the first anniversary of the date of grant.
Key Figures
RSUs exercised: 400 Restricted Stock Units
RSU exercise price: $0.0000 per unit
Common shares acquired: 400 shares
+3 more
6 metrics
RSUs exercised
400 Restricted Stock Units
Derivative transaction on August 6, 2026, code M
RSU exercise price
$0.0000 per unit
Reported price per RSU for the derivative transaction
Common shares acquired
400 shares
Common Stock received upon RSU conversion on August 6, 2026
Common shares held after
400 shares
Direct ownership of Aptevo common stock following the transaction
Original RSU grant (post-split)
400 RSUs
Granted August 6, 2025; vesting on first anniversary of grant
Original RSU grant (pre-split)
7,200 RSUs
Footnote disclosure of grant size before split adjustment
Key Terms
Restricted Stock Unit, derivative security, par value, post-split
4 terms
Restricted Stock Unit financial
"Restricted Stock Units ("RSUs") convert into common stock, $0.001 par value per share"
A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.
derivative security financial
"transaction code "M" described as Exercise or conversion of derivative security"
A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.
par value financial
"common stock, $0.001 par value per share, of the Issuer"
Par value is the fixed amount printed on a bond or stock that represents its original value when issued. It’s like the face value of a coin or bill—what the issuer promises to pay back or the starting price of a stock—though it often doesn’t change with market prices. It matters because it helps determine certain financial details, like how much the company will pay back at maturity.
post-split financial
"the reporting person was granted 7,200 (400 post-split) RSUs"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did Aptevo Therapeutics (APVO) report for Daniel Abdun-Nabi?
Daniel Abdun-Nabi reported exercising 400 Restricted Stock Units that converted into 400 shares of Aptevo common stock on August 6, 2026. This reflects an equity award conversion rather than an open-market purchase or sale.
What happened to the Restricted Stock Units in the Aptevo Therapeutics (APVO) Form 4?
The filing shows that 400 Restricted Stock Units were exercised/converted, reducing the RSU balance to zero. Each RSU converted into one share of Aptevo common stock, consistent with the one-for-one RSU conversion terms.
Were the Aptevo Therapeutics (APVO) insider transactions open-market buys or sells?
No. The transactions are coded “M” for exercise or conversion of derivative security, indicating RSUs converting into common stock. The summary data shows no open-market purchases or sales in this Form 4.
What do the footnotes in the Aptevo Therapeutics (APVO) Form 4 say about the RSUs?
Footnotes state the RSUs convert into common stock on a one-for-one basis and that on August 6, 2025, the reporting person was granted 7,200 RSUs (400 post-split), vesting on the first anniversary of the grant date.
AI-generated analysis. How Rhea-AI works. Not financial advice.
